Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seema A Bhat

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Blood|August 2, 2022
Ventricular arrhythmias and sudden death events following acalabrutinib initiationSeema A Bhat, John Gambril, Leylah Azali, et al.
Cancer Discovery|January 10, 2020
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic LeukemiaJennifer A Woyach, James S Blachly, Kerry A Rogers, et al.
Journal of Hematology & Oncology|July 14, 2022
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiationSunnia T Chen, Leylah Azali, Lindsay Rosen, et al.
Leukemia Research|July 23, 2022
Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemiaMirela Anghelina, Michelle J Naughton, Qiuhong Zhao, et al.
Blood Advances|October 8, 2020
Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonistsKristin L Koenig, Ying Huang, Emily K Dotson, et al.
Cancer Discovery|November 6, 2023
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin LymphomaJennifer A Woyach, Deborah M Stephens, Ian W Flinn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2026
Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with IbrutinibShanmugapriya Thangavadivel, Jami Shaffer, Shrilekha Misra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic LeukemiaKerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Lancet (London, England)|July 9, 2026
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trialMatthew S Davids, Toby A Eyre, Jennifer A Woyach, et al.
Journal for Immunotherapy of Cancer|July 7, 2026
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphomaFarrukh T Awan, Joshua T Gamse, Marije B Overdijk, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Blood|August 2, 2022
Ventricular arrhythmias and sudden death events following acalabrutinib initiationSeema A Bhat, John Gambril, Leylah Azali, et al.
Cancer Discovery|January 10, 2020
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic LeukemiaJennifer A Woyach, James S Blachly, Kerry A Rogers, et al.
Journal of Hematology & Oncology|July 14, 2022
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiationSunnia T Chen, Leylah Azali, Lindsay Rosen, et al.
Leukemia Research|July 23, 2022
Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemiaMirela Anghelina, Michelle J Naughton, Qiuhong Zhao, et al.
Blood Advances|October 8, 2020
Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonistsKristin L Koenig, Ying Huang, Emily K Dotson, et al.
Cancer Discovery|November 6, 2023
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin LymphomaJennifer A Woyach, Deborah M Stephens, Ian W Flinn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2026
Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with IbrutinibShanmugapriya Thangavadivel, Jami Shaffer, Shrilekha Misra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic LeukemiaKerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Lancet (London, England)|July 9, 2026
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trialMatthew S Davids, Toby A Eyre, Jennifer A Woyach, et al.
Journal for Immunotherapy of Cancer|July 7, 2026
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphomaFarrukh T Awan, Joshua T Gamse, Marije B Overdijk, et al.
Pageof 3